D49- neoplasms
A study to find which drug (metoclopramide, thalidomide, prochlorperazine, or lorazepam) is best to treat vomiting due to chemotherapy in patients with cancer.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Registry summary (technical)
An open-label phase III randomized controlled trial comparing metoclopramide, thalidomide, prochlorperazine, and lorazepam for treating breakthrough chemotherapy-induced nausea and vomiting in patients receiving olanzapine as part of antiemetic prophylaxis for highly emetogenic chemotherapy. - Nil
Sponsor: Cancer Institute WIA
CTRI/2024/08/072429 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 22 Jun 2026 · read by us 5 Nov 2026